Cardiac atrial muscle cells produce a polypeptide hormone that plays a role in the control of water and electrolyte balance and blood pressure. The circulating form of this hormone is the atrial natriuretic peptide (ANP), which contains 28 amino acids. Various immunohistochemical studies have shown that ANP is present in many 'areas of the central nervous system, including the median eminence. In our studies, we investigated the effect of ANP in a superfused rat pituitary cell system. When ANP was administered at increasing concentrations (0.01 /AM to 1 ,.M), it caused a significant doserelated stimulation of the release of luteinizing hormone (LU) and follicle-stimulating hormone (FSH). The lowest effective dose of ANP in our system was 0.03 ,AM. When ANP and LH-releasing hormone were administered together, the response was prolonged and had the characteristics of ANPstimulated LH and FSH release. In contrast with some previous reports, ANV in high concentration (i IAM) consistently induced a small but significant stimulation of the release of corticotropin. ANP did not influence the basal release of prolactin, growth hormone, and thyrotropin.
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DeBold et al. (1) (2) (3) were the first to report that the heart atrial muscle cells produce a polypeptide that they named the atrial natriuretic factor (ANF). These findings were confirmed by others (4, 5) . Recently, other groups isolated rat and human atrial peptides and determined their amino acid sequences. (For review, see ref. 6 .) The cloning and sequence analysis of the complementary DNA encoding the ANF precursor revealed that ANF is synthesized in the rat in a prepro form containing 152 amino acids (7, 8) . Different peptides consisting of the C-terminal 25-30 amino acids of prepro-ANF have full biological activity and have been also called atrial natriuretic factors (9) . However, the circulating form of ANF appears to be cardionatrin I or a-rat atrial natriuretic peptide (ANP), a 28-amino acid peptide that comprises residues 123-150 of prepro-ANF (9) . ANP is the most potent endogenous natriuretic/diuretic substance described to date; it decreases blood pressure and has an inhibitory effect on renin and aldosterone secretion (1, 3, 1Q). Recent immunohistochemical studies and tests based on RIAs indicate that ANF is present in the central nervous system. ANF-like immunoreactivity has been also detected in whole hypothalamic extracts (11) . Jacobowitz et al. reported that ANFpositive nerve fibers and cell bodies can be observed in the preoptic area, hypothalamus, mesencephalon, and pons of rats (12) . In colchicine-treated animals, they found a large number of ANF-immunoreactive cell bodies also in the organon vasculosum of the lamina terminalis and hypothalamic nuclei. In addition, they detected ANF-positive fibers in the external zone of the median eminence. Immunohistochemical results of Saper et al. (13) and Nakao et al. § confirmed these findings. Since ANF is present immunocytochemically in the median eminence, there is a possibility that it may act also on the pituitary through the portal circulation. Anand-Srivastava et al. (14) demonstrated that ANF has an inhibitory effect on pituitary adenylate cyclase and suggested that ANF inhibits the release of corticotropin (ACTH) at high concentration. In view ofthese findings and the growing evidence that some peptides discovered in the peripheral organs may play a physiological role in the central nervous system and the anterior pituitary gland, we decided to investigate the effect of ANP in the superfused rat pituitary cell system.
MATERIALS AND METHODS
Pituitary cells originating from 6 or 12 female Sprague-Dawley rats (160-180 g) at random stages of the estrus cycle were used in each chamber of the superfusion apparatus. The preparation of the cells and the superfusion apparatus were very similar to that described by Vigh and Schally (15) . The rats were decapitated, and the anterior pituitaries were removed, cut into small pieces, incubated with collagenase (Worthington, type I), dispersed, mixed with 0.9 ml of swollen Sephadex G-10 that had been preequilibrated with oxygenated tissue culture medium (medium 199, Sigma), and transferred into the superfusion chamber. The cells were perfused overnight with the medium at a flow rate of 20 ml/hr. Collection of 1-ml (16) .
RESULTS
In the superfused rat pituitary cell system, ANP elevated LH and FSH secretion in a dose-related manner (Fig. 1) . LH release and FSH release were stimulated to a greater extent with increasing doses of ANP. The lowest effective dose was 0.03 ,uM ANP. When the LH and FSH peaks elicited by ANP (Fig. 1) and LH-RH (Fig. 2) were compared, the effect of ANP on LH and FSH release was found to be more prolonged. Although the effect of LH-RH was concluded in 9-12 min, it required 24-36 min to recover a stable baseline after administering ANP at different dose levels. When LH-RH and ANP were given together, the response was prolonged and had the characteristics of ANP-stimulated LH and FSH release. However, the secretion in the first 9 min was additive only when larger doses of LH-RH and ANP (1 nM and 0.3 /iM, respectively) were infused onto the column (Fig. 2) . In contrast to the results of Anand-Srivastava et al. (14), we did not detect any inhibition of the release of ACTH from the anterior pituitary cells by ANP, even at very high (1 uM) concentration. On the contrary, in our system at this dose, ANP slightly, but consistently, elevated the ACTH level. Simultaneous infusion of 1 ,uM ANP did not influence the ACTH release elicited by 0.2 nM CRF (Fig. 3) . Administra- tion of ANP at different concentrations had no effect on prolactin (Fig. 4) , GH, and TSH release (data not shown).
To exclude the possibility that the prolonged effect of ANP was due to its adsorption to Sephadex G-10, we tested the clearance of iodinated ANP from the column. No adsorption was found when 125I-labeled ANP and unlabeled ANP were administered in a 1:4 ratio, at a final concentration of 0.1 uM or 0.3 gM for 6 min. Three minutes after stopping the infusion, 95% of the iodinated ANP was cleared from the column.
DISCUSSION
ANF is reported to inhibit adenylate cyclase in different tissues (17) , including the anterior and posterior pituitary (14) . The vasorelaxant action of ANF is associated with an increase in cyclic GMP in plasma and vascular smooth muscle (18 (27) . Analyzing serial sections of rat adenohypophysis they demonstrated ANF-like immunoreactivity in the LH-and FSHpositive cells. They suggest that this endogenously synthesized or stored ANF may play a role in the secretion ofACTH by corticotroph cells. Our results do not support the role of ANF in regulating ACTH secretion, although this would have been most plausible. However, the immunocytochemical presence of ANF in gonadotrophs and the fact that in the superfused rat pituitary cell system ANF stimulates the release of LH and FSH will require additional research to clarify the possible role of ANF in these mechanisms.
